Deciphera Pharmaceuticals, LLC

Eli Lilly and Company

Bryan D Smith

Daniel L Flynn

Michael D Kaufman

Rodrigo Ruiz Soto

Keisuke Kuida

Philip Arthur Hipskind

James Robert Henry

Lakshminarayana Vogeti

Sheng-Bin Peng

Scott Wise

Wei-Ping Lu

Anu Gupta

Timothy Malcolm Caldwell

William C Patt

Marc Rudoltz

Oliver Rosen

Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).

Methods of treating disorders using CSF1R inhibitors

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP pathway inhibitor such as for example a RAS, RAF, MEK, or ERK inhibitor for the treatment of mastocytosis.

Combination therapy for the treatment of mastocytosis

A semi-trailer aerodynamic drag deflection assembly for reducing aerodynamic drag upon all surfaces of the semi-trailer includes a pair of interior walls positioned against a respective one of a pair of lateral surfaces of a semi-trailer. A plurality of vents is positioned from an inner surface to an outer surface of the interior wall. A pair of exterior walls is positioned against a respective one of the pair of interior walls. An outside surface of each of the exterior walls has a plurality of indents for deflecting wind An undercarriage has a pair of side walls with a storage being positioned between each of the side walls. Each of the side walls has a plurality of fins directing aerodynamic drag from the bottom surface of the semi-trailer into each of the vents of each of the interior walls. A pair of doors provides access to the storage of the undercarriage.

Semi-trailer aerodynamic drag deflection assembly

The present disclosure relates to the use of 1-[4-bromo-5-[1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl]-2-fluorophenyl]-3-phenylurea or 1-(5-(7-amino-1-ethyl-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-4-bromo-2-fluorophenyl)-3-phenylurea, or a pharmaceutically acceptable salt thereof, in combination with a MAPKAP kinase inhibitor for the treatment of cancers, including c-KIT-mediated cancers, such as GIST.

Combination therapy for the treatment of gastrointestinal stromal tumor

The present invention relates to methods of inhibiting TIE2 kinase useful in the treatment of tumor growth, invasiveness, intravazation, dissemination, metastasis, and immunosuppression. Specifically, the invention relates to methods of using 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and salts thereof of Formula I.

Methods for inhibiting tie-2 kinase useful in the treatment of cancer

This invention provides compounds of Formula I: (Formula I should be inserted here) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula I; and use of a compound of Formula I for treating specified cancers. 

RAF inhibitor compounds

This invention provides compounds of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising a compound of Formula (I); and use of a compound of Formula (I) for treating specified cancers. 

Growing community of inventors

Lawrence, KS, United States of America

Bryan D Smith